Online Psychoeducation Boosts Clinic-Based Quit Care, Trial Finds

Quitting smoking is one of the most stubborn behavioral challenges in medicine, and even the best clinics struggle to keep patients on track once they walk out the door. A new randomized controlled trial from Turkey suggests that a low-cost digital supplement can meaningfully tip the odds. Researchers at Ege University enrolled 208 adults seeking treatment at the university’s Smoking Cessation Clinic and found that adding a structured online psychoeducation program to routine clinical care led to measurable short-term reductions in both cigarette consumption and nicotine dependence compared with routine care alone. The findings, published in Current Psychology, arrive at a moment when health systems worldwide are searching for scalable ways to strengthen face-to-face cessation services without inflating staff workloads.

The trial’s design was straightforward but rigorous in its statistical handling. Participants were systematically allocated into two groups of roughly equal size: 103 people received the standard clinic program plus access to the web-based psychoeducation modules, while 105 received routine care alone. The researchers tracked three primary outcomes at a one-month follow-up: the number of cigarettes smoked per day, scores on the Fagerström Test for Nicotine Dependence (FTND), and smoking status. Secondary measures included the participant’s stage of change within the Health Action Process Approach, a well-established psychological model of health behavior, and mental well-being as assessed by a validated scale.

The results on dependence and consumption were the trial’s clearest signals. In the primary analysis, which used multiple imputation to account for missing follow-up data under a missing-at-random assumption, the intervention group scored on average 1.18 points lower on the FTND than controls, with a 95 percent confidence interval spanning from 1.58 to 0.79 points below. Daily cigarette consumption told a similar story: the web-supported group smoked 4.18 fewer cigarettes per day on average, with a confidence interval of 5.63 to 2.73 fewer. For context, the Fagerström test ranges from zero to ten, and even single-point shifts are clinically meaningful predictors of quit success, since higher dependence scores consistently forecast lower abstinence rates in pooled clinical trial data.

Sensitivity analyses using only complete cases, meaning participants with full follow-up data, pointed in the same direction and were, if anything, more pronounced. In that subset, the FTND difference grew to 1.88 points and the consumption difference to 6.47 cigarettes per day, both statistically significant. The effect on complete abstinence was more delicate. Under the multiple imputation framework, the abstinence benefit did not reach statistical significance, but in the complete-case analysis the intervention group showed nearly threefold higher odds of quitting, with an odds ratio of 2.88 and a confidence interval of 1.01 to 8.19. The authors are careful to note that this abstinence result should be interpreted cautiously, given its sensitivity to how missing data were handled, a common tension in smoking research where follow-up loss is notoriously high.

That tension deserves a technical word, because it sits at the heart of how cessation trials are judged. Smokers who relapse often drop out of studies, and treating dropouts as failures versus imputing their outcomes can swing conclusions dramatically. Multiple imputation, the method used in the primary analysis here, generates several plausible datasets that fill in missing values based on observed patterns, then pools the results to reflect uncertainty honestly. The complete-case analysis, by contrast, simply discards incomplete records, which can bias estimates if those who stayed in the study were systematically more motivated. The fact that both approaches agreed on dependence and consumption, but diverged on abstinence, suggests the digital program reliably reduces smoking intensity even when its effect on full quitting remains harder to pin down at one month.

The theoretical engine behind the online program is the Health Action Process Approach, developed by health psychologist Ralf Schwarzer and colleagues. The model divides behavior change into a motivation phase, where people form intentions based on outcome expectancies and risk perceptions, and a volition phase, where planning and self-efficacy convert intentions into sustained action. Digital psychoeducation fits this architecture naturally: modules can walk users through the psychological mechanics of craving, cue reactivity, and relapse loops, then support the critical transition from deciding to quit to actually maintaining abstinence day by day. The trial’s measurement of stage of change within this framework reflects an effort to capture not just whether people quit, but how their psychological readiness shifted along the way.

The study also taps into a broader evidence base on blended care. Systematic reviews of internet-based cessation interventions, including Cochrane reviews, have found that interactive and tailored web programs can improve cessation rates compared with non-active controls, and reviews of blended treatment, combining face-to-face and online components, suggest the combination may outperform either alone for behavioral health conditions. What has been less clear is whether digital add-ons deliver measurable benefit on top of an already intensive clinical program, which is a much higher bar than beating a waitlist or a pamphlet. This trial addresses exactly that gap in a real-world clinic setting, where patients also typically receive behavioral counseling and, in many cases, pharmacotherapy as part of routine national cessation services.

Practically, the appeal of the intervention lies in its economics and its scalability. A clinic-based program requires trained staff, scheduled appointments, and physical infrastructure, all of which constrain how many smokers a health system can treat. An online psychoeducation component, once built, can be extended to every enrolled patient at near-zero marginal cost, potentially extending the reach of specialized clinics to primary care settings, rural populations, and smokers who cannot attend frequent in-person visits. Given that tobacco remains a leading preventable cause of death globally, and that the World Health Organization issued its first clinical treatment guideline for tobacco cessation in 2024 to push evidence-based care into routine practice, tools that amplify existing clinical capacity are precisely what implementation scientists have been calling for.

The study is not without limitations that temper enthusiasm. The follow-up window of one month captures the acute early phase of cessation but says nothing about whether the digital program’s effects persist through the relapse-prone months that follow, when most quitters eventually return to smoking. The allocation was systematic rather than fully random in the conventional sense, and the trial was retrospectively registered with ClinicalTrials.gov under identifier NCT06945770, a practice that transparency advocates generally discourage. Self-reported smoking status, while widely used, can diverge from biochemical verification. Still, the concordance between the imputation-based and complete-case analyses on the core outcomes of dependence and consumption lends credibility to the central claim: that accessible online psychoeducation, layered onto standard clinical care, makes smokers measurably less dependent within weeks.

For clinicians and policymakers, the takeaway is pragmatic rather than revolutionary. Digital psychoeducation is not a substitute for the counseling, medical evaluation, and social support that cessation clinics provide, but this trial suggests it is a worthwhile amplifier. If future studies with longer follow-up and biochemical verification confirm the pattern seen here, the standard prescription for a smoker entering a clinic may soon include not just an appointment and possibly medication, but a structured online curriculum that keeps working between visits, at the precise psychological moments, late-night cravings, stressful days, moments of wavering resolve, where face-to-face care is absent and relapse risk is highest.

Subject of Research: Effectiveness of a web-based psychoeducation program as an add-on to routine smoking cessation clinical treatment

Article Title: Web-based smoking intervention as an add-on to routine smoking cessation clinical treatment: a randomized controlled trial

Article References: Altin, D., Yararbas, G., & Hassoy, H. (2026). Web-based smoking intervention as an add-on to routine smoking cessation clinical treatment: a randomized controlled trial. Current Psychology, 45(17), Article 1436. https://doi.org/10.1007/s12144-026-09952-3

Image Credits: AI Generated

DOI: 10.1007/s12144-026-09952-3

Keywords: smoking cessation, web-based intervention, psychoeducation, randomized controlled trial, nicotine dependence, Fagerström Test, Health Action Process Approach, digital health, public health, Ege University, behavior change, mental well-being